secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-009819
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cabaletta announces 2026 priorities: myositis trial enrolling, BLA 2027, Cellares IND cleared
--------------------------------------------------------------------------------

- Myositis registrational cohort actively enrolling; BLA submission for rese-cel projected in 2027.
- FDA aligned on registrational cohort designs in SLE and LN, each ~25 patients with unique endpoints.
- FDA granted RMAT designation for rese-cel in systemic sclerosis; registrational alignment expected 1H26.
- IND amendment cleared for Cellares automated manufacturing; clinical manufacturing data due 1H26.
- No-preconditioning dose-escalation in PV ongoing; Phase 1/2 data from 3 trials expected 1H26.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000119312526009819/0001193125-26-009819-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000119312526009819/caba-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-009819

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer